Marlborough, MA – Sunovion Pharmaceuticals Inc.has announced that new analyses of clinical and health outcomes data for Brovana (arformoterol tartrate) Inhalation Solution will be presented at the 2016 American Thoracic Society International Conference (ATS 2016), which is scheduled to take place May 13-18, 2016 in San Francisco, California.
Sunovion will present post-hoc analyses using data from a long-term safety study evaluating BROVANA use in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). Results from a prospective health outcomes study assessing the prevalence of low peak inspiratory flow rate among real world COPD patients will also be presented.
“COPD is a chronic and progressive disease affecting more than 15 million adults in the U.S. and is the third leading cause of death in the U.S.,” said Krithika Rajagopalan, vice president, head of global health economics and outcomes research at Sunovion. “COPD exacerbations adversely impact a person’s quality of life and also impose a substantial economic burden on the health system. Our aim is to provide treatments that can improve health outcomes for the COPD community, and the data being presented at ATS showcases Sunovion’s continued commitment to providing safe and effective treatment options for people with COPD.”
For additional information about Sunovion’s presentations at ATS 2016, a full prescribing information and medication guide for BROVANA (arformoterol tartrate) Inhalation Solution and safety information, visit sunovion.com, sunovion.eu and sunovion.ca.
You are encouraged to report negative side effects of prescription drugs to the FDA by visiting fda.gov/medwatch or calling 1-800-FDA-1088.
